Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia

BeiGene

2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib.

BeiGene today announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinaemia.

Read BeiGene press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada